Rho kinase inhibitor for primary open-angle glaucoma and ocular hypertension

Josefine Clement Freiberg; Alexander von Spreckelsen; Naira Khachatryan; Miriam Kolko; Augusto Azuara-Blanco; Gianni Virgili

doi:10.1002/14651858.CD013817

Rho kinase inhibitor for primary open-angle glaucoma and ocular hypertension

Josefine Clement Freiberg^*, Alexander von Spreckelsen, Naira Khachatryan, Miriam Kolko, Augusto Azuara-Blanco, Gianni Virgili

^*Corresponding author for this work

Research output: Contribution to journal › Article › peer-review

12 Citations (Scopus)

Abstract

Objectives: This is a protocol for a Cochrane Review (intervention). The objectives are as follows:. To compare the efficacy and safety of rho kinase inhibitors to placebo or other glaucoma medication in people diagnosed with open-angle glaucoma or ocular hypertension.

Original language	English
Article number	CD013817
Journal	Cochrane Database of Systematic Reviews
Volume	2020
Issue number	12
DOIs	https://doi.org/10.1002/14651858.CD013817
Publication status	Published - 16 Dec 2020

Bibliographical note

Funding Information:
Thank you to the Cochrane Eyes and Vision (CEV) Information Specialist, who created and will execute the electronic search strategies. We thank Renee F. Wilson from CEV@US for her helpful feedback. We thank the following peer reviewers for their feedback: Renee Bovelle (Howard University) and Anthony King (Spire Nottingham Hospital). This protocol was managed by CEV@US and was signed off for publication by Tianjing Li and Richard Wormald.

Publisher Copyright:
Copyright © 2020 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

Copyright:
Copyright 2021 Elsevier B.V., All rights reserved.

ASJC Scopus subject areas

Pharmacology (medical)

Access to Document

10.1002/14651858.CD013817Licence: Unspecified

Cite this

@article{6884778398724c96a69de9b288876950,

title = "Rho kinase inhibitor for primary open-angle glaucoma and ocular hypertension",

abstract = "Objectives: This is a protocol for a Cochrane Review (intervention). The objectives are as follows:. To compare the efficacy and safety of rho kinase inhibitors to placebo or other glaucoma medication in people diagnosed with open-angle glaucoma or ocular hypertension.",

author = "\{Clement Freiberg\}, Josefine and \{von Spreckelsen\}, Alexander and Naira Khachatryan and Miriam Kolko and Augusto Azuara-Blanco and Gianni Virgili",

note = "Funding Information: Thank you to the Cochrane Eyes and Vision (CEV) Information Specialist, who created and will execute the electronic search strategies. We thank Renee F. Wilson from CEV@US for her helpful feedback. We thank the following peer reviewers for their feedback: Renee Bovelle (Howard University) and Anthony King (Spire Nottingham Hospital). This protocol was managed by CEV@US and was signed off for publication by Tianjing Li and Richard Wormald. Publisher Copyright: Copyright {\textcopyright} 2020 The Cochrane Collaboration. Published by John Wiley \& Sons, Ltd. Copyright: Copyright 2021 Elsevier B.V., All rights reserved.",

year = "2020",

month = dec,

day = "16",

doi = "10.1002/14651858.CD013817",

language = "English",

volume = "2020",

journal = "Cochrane Database of Systematic Reviews",

issn = "1465-1858",

publisher = "John Wiley \& Sons Ltd",

number = "12",

}

TY - JOUR

T1 - Rho kinase inhibitor for primary open-angle glaucoma and ocular hypertension

AU - Clement Freiberg, Josefine

AU - von Spreckelsen, Alexander

AU - Khachatryan, Naira

AU - Kolko, Miriam

AU - Azuara-Blanco, Augusto

AU - Virgili, Gianni

N1 - Funding Information: Thank you to the Cochrane Eyes and Vision (CEV) Information Specialist, who created and will execute the electronic search strategies. We thank Renee F. Wilson from CEV@US for her helpful feedback. We thank the following peer reviewers for their feedback: Renee Bovelle (Howard University) and Anthony King (Spire Nottingham Hospital). This protocol was managed by CEV@US and was signed off for publication by Tianjing Li and Richard Wormald. Publisher Copyright: Copyright © 2020 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd. Copyright: Copyright 2021 Elsevier B.V., All rights reserved.

PY - 2020/12/16

Y1 - 2020/12/16

N2 - Objectives: This is a protocol for a Cochrane Review (intervention). The objectives are as follows:. To compare the efficacy and safety of rho kinase inhibitors to placebo or other glaucoma medication in people diagnosed with open-angle glaucoma or ocular hypertension.

AB - Objectives: This is a protocol for a Cochrane Review (intervention). The objectives are as follows:. To compare the efficacy and safety of rho kinase inhibitors to placebo or other glaucoma medication in people diagnosed with open-angle glaucoma or ocular hypertension.

U2 - 10.1002/14651858.CD013817

DO - 10.1002/14651858.CD013817

M3 - Article

AN - SCOPUS:85103018763

SN - 1465-1858

VL - 2020

JO - Cochrane Database of Systematic Reviews

JF - Cochrane Database of Systematic Reviews

IS - 12

M1 - CD013817

ER -

Rho kinase inhibitor for primary open-angle glaucoma and ocular hypertension

Abstract

Bibliographical note

ASJC Scopus subject areas

Access to Document

Fingerprint

Cite this